Joint Pain Injections Market Size 2020 | Covid 19 Impact Analysis | Global Industry Trends, Growth, Share, Size and Forecast – StartupNG

Market Scenario of the Joint Pain Injections Market:

The industry study on Joint Pain Injections outlines national and global business prospects and competitive scenarios for Joint Pain Injections. Estimation of market size and projections were given based on a unique research design tailored to the complexities of the Joint Pain Injections.

Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-65228?utm_source=SNG/KK

The prominent players covered in this report: Anika Therapeutics, Inc., Bioventus, Ferring Pharmaceuticals Inc., Sanofi, Zimmer Biomet.

Major regions covered in the study include North America, Europe, Asia Pacific, Middle East & Africa, And South America.

The Joint Pain Injections market has been segmented By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections)By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint). Also, key factors impacting the growth of the Joint Pain Injections market have been identified with potential gravity.

Years Covered in the Study:

Historic Year: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2028

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-65228?utm_source=SNG/KK

The Joint Pain Injections market report comprises domestic and global markets. This study on Joint Pain Injections market compiles internationally influential players and their business strategies to understand industry strategies. Some points that are the highlights are:

Reasons for buying this report:

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-65228?utm_source=SNG/KK

About Us:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Read more here:
Joint Pain Injections Market Size 2020 | Covid 19 Impact Analysis | Global Industry Trends, Growth, Share, Size and Forecast - StartupNG

Porzingis hoping to play again this season if Mavs can get past Clippers – The Official Home of the Dallas Mavericks – Mavs.com

Kristaps Porzingis isnt quite sure if the lateral menisus tear in his right knee will eventually require surgery. But the Dallas Mavericks forward is holding out hope that it wont.

An MRI performed earlier this week revealed the tear, and Porzingis said he had been taking some Platelet-Rich Plasma (PRP) injections to help alleviate the pain.

Were hoping with the injections that it could help me, Porzingis said on Saturday. Hopefully the meniscus can kind of I dont know how it works exactly but repair itself with the injections.

But it depends on how Im going to feel in the next two weeks and then I think the medical staff is going to make a decision whether I need that (surgery) or not.

One thing is for sure: Porzingis wont play in Game 6 of the Mavs Western Conference quarterfinals series against the Los Angeles Clippers. The game tips off Sunday at 2:30 p.m. inside the NBA bubble with the Clippers leading the series, 3-2.

Porzingis also hasnt been medically cleared to play if the series between the Mavs and Clippers reaches a Game 7.

My hope is that if we have a chance to advance (to the conference semifinals), maybe somehow I can get the knee better and play, Porzingis said. I tried to go now and practice, and it just wasnt the medical staff just didnt accept me playing and doing more.

So for now, I dont know. Im going to be here, because if I was able to play through it, then maybe I can keep playing through it at some point. Just now Im doing intense treatment and doing all I can to improve the knee, and then well see where we go.

Porzingis said he originally injured his knee while battling for an offensive rebound in the first half of Game 1 of this series. But he continued to play in that game, and in the ensuing two contests before missing the past two games.

I think somebody kind of fell on (the knee), Porzingis said. I think it was (Marcus) Morris (Sr.), on accident, obviously, and I felt something in my knee. But I just kept playing through it, and then at halftime I told the medical staff my knee was bothering me a little bit.

They worked on it and I was good to go in the second half, and thats when I got ejected and then my knee locked up after Game 1. Somehow we were able to get it going (for Game 2) it felt good.

However, Porzingis said in Game 3 his knee got worse. And just before the tipoff of Game 4, the pain in his knee was so excruciating that Porzingis was a last-minute scratch.

Right before the game (4) I just couldnt get anything going and its super disappointing, super frustrating, he said. But Ive learned how to accept that feeling and look forward to whats next.

Porzingis has learned how to accept that feeling because of what happened to him on Feb. 6, 2018. Thats the day Porzingis tore his left anterior cruciate ligament after landing awkwardly following a dunk in a road game against the Milwaukee Bucks while he was playing for the New York Knicks.

Porzingis underwent surgery on Feb. 13, 2018, was traded to the Mavs on Jan, 31, 2019, and made his Mavs debut on opening day this season.

So as far as knee injuries go, Porzingis has been there, done that. And the Mavs hope his right knee responds favorably to treatment and hell be able to play if they can somehow win two more games against the Clippers.

The door is not closed on the entire season if we are able to advance, coach Rick Carlisle said. When I spoke to you (media) guys on Wednesday about this, he had practiced, he was sore. It was clear that hes doing everything that he can.

The guys been doing treatment, I dont know, 10 hours a day. . .and it just wasnt progressing the way that he had hoped. He was on the floor today and did some shooting and did a little bit of moving around, so he wants to keep the door open to possibly play if we can move on, but its a very tough situation, but hes trying his best.

Someone asked Porzingis if he was worried about his future in the NBA due to injuries to each of his two knees, or if he thought these were just isolated incidents. His response?

I cant really be too worried about that, Porzingis said. Both of (the injuries) were contact injuries, and these things happen. What I can do is focus on the work that I can put in to make sure that I decrease the possibility of that happening.

That means strengthening everything and just trying to do all of the preventive work I can, and thats in my hands. Again, its a contact sport and these things can happen, so I cant be too frustrated over these kinds of things.

At the time of his injury, Porzingis was playing some of the best basketball of his career. Overall, the 7-3, 240-pounder averaged 20.4 points, 9.5 rebounds and 2.0 blocks per game this season.

Also, Porzingis had 34 points and 13 rebounds in Game 3 against the Clippers. Its the first time a member of the Mavs produced a 30-point, 10-rebound game in the postseason since Dirk Nowitzki collected 34 points and 11 rebounds in Game 3 of the 2011 NBA Finals against the Miami Heat.

Clearly, Porzingis is a major centerpiece to what the Mavs are trying to get accomplished.

Obviously I was (feeling) bad for a little bit for a little while once I found out what happened in the knee, Porzingis said. But I was able to accept that feeling and move past that pretty quickly and look into whats next and go on from there. Obviously if this is the end for my season, it has a bitter end, although I think my year as it went on I got into a better rhythm and I started playing better basketball with each game.

I feel like now once I go into the offseason and make sure I get the knee healthy, Im looking forward to just thinking picking up where I left off and keep playing that high level of basketball and look forward to the next things we can accomplish as a team.

Still, Porzingis shrugs at the mere thought that he may have played his last game this season.

Ive got to thank the medical staff, he said. They put in crazy hours with me and in the treatment room and in the weight room. But at this point it was just a little too much maybe, and they dont want me to push it any more, so were here and were going day-by-day.

Its hard to not be able to be out there with the guys and fight, especially in a series like this thats so much fun. Its really tough and frustrating, but it is what it is and now Im looking forward to getting healthy.

Twitter: @DwainPrice

More here:
Porzingis hoping to play again this season if Mavs can get past Clippers - The Official Home of the Dallas Mavericks - Mavs.com

5 Recent Tech Innovations Disrupting the Medical and Healthcare Industry – HealthTechZone

Technology is at our fingertips. Think of all the health monitors or wearable fitness trackers that people are using today. Virtual healthcare practices have changed our attitude towards the medical and healthcare industry. While there are loyalists as well as dissenters who rue the lack of personal connection with the doctor and quality care, tech innovations are breaking barriers meanwhile.

Technology in Healthcare

It could be as simple as information sharing between doctors and patients, or something as profound as robotic aid in a high-risk surgery. Better still, make it a remote surgery where the patient and doctor are separated by miles in between them! Clearly, recent tech advancements are disrupting the medical and healthcare industry with its dynamic applications.

It started with the online consultations and took off from there.

Telemedicine or virtual consultations are a thing of the past now. Even when they started, the dramatic impact it had on traditional healthcare roles has changed our collective attitude towards the industry. As these technologies develop further, more applications for professionals and patients stand to promote the overall wellness. Today, apps on the phone track our exercise and calorie intake, check obesity development, and monitor heart health.

Here are 5 recent tech innovations that have disrupted the industry for the long haul:

1. Virtual Reality or AR/MR/VR in Healthcare

Both medical professionals and patients stand to benefit from the multi-sensory, immersive experience that VR provides.

Think of realistic and low-risk simulated environment for training surgeons. On the other hand, in the arena of pain management or mental health, immersion in virtual worlds can produce better results. VRs therapeutic potential and rehabilitation chances in acute pain and anxiety disorder cases are far-reaching.

2. Nanomedicine

This is the stuff of sci-fi genres. Nanotechnology and nanodevices are arming the healthcare industry with control on the molecular level. Nanopharmaceuticals are aiming at smaller drugs and more precise delivery systems. For instance, delivering chemotherapy to targeted tumours rather than poisoning the whole body.

3. 3D Printing

Creating medical tools from buildable materials ranging from plastic to stem-cells, 3D printing has revolutionised the medical industry. Aided by the custom-friendly aspect of 3D printing, organ transplants and tissue repair, prosthetics and braces, even layered stem-cell organoids are possible today. Faster prototypes at a fraction of the traditional cost is a huge leg-up in the healthcare scene. The most dazzling innovation through this method is the poly-pill that holds several drugs for multiple illnesses with different release times!

4. Internet of Medical Things or IoT

Connected devices, cloud-computing, and the internet have allowed a larger the exchange of data, convenience, and automation. The IoT is significantly changing how healthcare professionals can manage patient records, control inventory, monitor and provide preventative care. In a way, this could be the most significant disruptive technology as a lot of other tech advancements have been possible only through this.

5. Precision Medicine

Diagnosis, treatment, and preventive care based on an individuals environment, lifestyle, and genetic makeup is a big shift from the all-purpose generic approach. Precision medicine is suggested based on diagnostic and molecular genetic testing processes such as genome sequencing and DNA mutation investigations. This will revolutionise preventive measures reducing treatment time and expenditure as well as healthcare requirement.

As healthcare and technological advancements grow together, the industry becomes more optimised providing quality care. It is evident in the cosmetic health industry where non-surgical procedures have advanced significantly. You can get Botox in Perth with breakthrough serums and great aftercare with minimal or no recovery time.

In fact, tech innovations have disrupted the healthcare industry so significantly, it is impossible to see it survive without them.

Follow this link:
5 Recent Tech Innovations Disrupting the Medical and Healthcare Industry - HealthTechZone

A New FMI Report Forecasts the Impact of COVID-19 Pandemic on Stem Cell Therapies Market Growth Post 2020 – The Scarlet

With 1000+ market research reports and 1 billion+ data points, Future Market Insights (FMI) serves each and every requirement of the clients operating in the global healthcare, pharmaceuticals, and medical device industries. FMI deploys digital intelligence solutions to offer compelling insights to report buyers that help them in overcoming market challenges, especially at the time of a crisis. Our dedicated team of professionals performs an extensive survey for gathering accurate information associated with the market.

FMI, in its upcoming business report, elaborates the historical and current scenario of the Stem Cell Therapies in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern and growth prospects.

Crucial information and forecast statistics covered in the Stem Cell Therapies report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

COVID-19 Impact Analysis on Stem Cell Therapies

The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Stem Cell Therapies. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Stem Cell Therapies.

Following governments measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.

The FMIs report includes an interesting chapter on preliminary impact of the COVID-19 on the Stem Cell Therapies. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.

Why Choose Future Market Insights

Discounted prices for new customers! Offer expires soon!

Request Report [emailprotected] https://www.futuremarketinsights.com/reports/sample/rep-gb-1087

Stem Cell Therapies market: segmentation

To analyze the Marketing Stem Cell Therapies effectively and efficiently, the information has been segregated into key segments and sub-segments.

On the basis of treatment:

On the basis of application:

Stem Cell Therapies: Competition Analysis

The FMIs study presents a comprehensive analysis of global, regional, and country-level players active in the Stem Cell Therapies. Competitive information detailed in the Stem Cell Therapies report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Stem Cell Therapies report.

Key players covered in the report include:

Request Methodology of this Report @ https://www.futuremarketinsights.com/askus/rep-gb-1087

Important Questions Answered in the Stem Cell Therapies Report

Key Offerings of the Report

About Us Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us Mr. Abhishek Budholiya 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 F: +1-845-579-5705 T (UK): + 44 (0) 20 7692 8790 Sales: [emailprotected] Press Office: [emailprotected] Blog: Market Research Blog Website: https:www.futuremarketinsights.com

Excerpt from:
A New FMI Report Forecasts the Impact of COVID-19 Pandemic on Stem Cell Therapies Market Growth Post 2020 - The Scarlet

Cell Harvesting Market 2018 Analysis Of Production, Future Demand, Sales And Consumption Research Report To 2023 – The Scarlet

The global market for cell harvesting should grow from $885 million in 2018 to reach $1.5 billion by 2023 at a compound annual growth rate (CAGR) of 11.3% for the period of 2018-2023.

Report Scope:

The scope of the report encompasses the major types of cell harvesting that have been used and the cell harvesting technologies that are being developed by industry, government agencies and nonprofits. It analyzes current market status, examines drivers on future markets and presents forecasts of growth over the next five years.

The report provides a summary of the market, including a market snapshot and profiles of key players in the cell harvesting market. It provides an exhaustive segmentation analysis of the market with in-depth information about each segment. The overview section of the report provides a description of market trends and market dynamics, including drivers, restraints and opportunities. it provides information about market developments and future trends that can be useful for organizations, including wholesalers and exporters. It provides market positionings of key players using yardsticks of revenue, product portfolio, and recent activities. It further includes strategies adopted by emerging market players with strategic recommendations for new market entrants. Readers will also find historical and current market sizes and a discussion of the markets future potential. The report will help market players and new entrants make informed decisions about the production and exports of goods and services.

Get Access to sample pages @https://www.trendsmarketresearch.com/report/sample/11685

Report Includes:

41 data tables and 22 additional tables Description of segments and dynamics of the cell harvesting market Analyses of global market trends with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023 Characterization and quantification of market potential for cell harvesting by type of harvesting, procedure, end user, component/equipment and region A brief study and intact information about the market development, and future trends that can be useful for the organizations involved in Elaboration on the influence of government regulations, current technology, and the economic factors that will shape the future marketplace Key patents analysis and new product developments in cell harvesting market Detailed profiles of major companies of the industry, including Becton, Dickinson and Co., Corning, Inc., Fluidigm Corp., General Electric Co., Perkinelmer, Inc., and Thermo Fisher Scientific, Inc.

Summary

Stem cells are unspecialized cells that have the ability to divide indefinitely and produce specialized cells. The appropriate physiological and experimental conditions provided to the unspecialized cells give rise to certain specialized cells, including nerve cells, heart muscle cells and blood cells. Stem cells can divide and renew themselves over long periods of time. These cells are extensively found in multicellular organisms, wherein mammals, there are two types of stem cells embryonic stem cells and adult stemcells. Embryonic stem cells are derived from a human embryo four or five days old that is in the blastocyst phase of development. Adult stem cells grow after the development of the embryo and are found in tissues such as bone marrow, brain, blood vessels, blood, skin, skeletal muscles and liver. Stemcell culture is the process of harvesting the exosomes and molecules released by the stem cells for the development of therapeutics for chronic diseases such as cancer and diabetes. The process is widely used in biomedical applications such as therapy, diagnosis and biological drug production. The global cell harvesting market is likely to witness a growth rate of REDACTED during the forecast period of 2018-2023.The value of global cell harvesting market was REDACTED in 2017 and is projected to reach REDACTED by 2023. Market growth is attributed to factors such as increasing R&D spending in cell-based research,the introduction of 3D cell culture technology, increasing government funding, and the growing prevalence of chronic diseases such as cancer and diabetes.

The growing incidence and prevalence of cancer is seen as one of the major factors contributing to the growth of the global cell harvesting market. According to the World Health Organization (WHO), cancer is the second-leading cause of mortality globally and was responsible for an estimated 9.6 million deaths in 2018. Therefore, there is an increasing need for effective cancer treatment solutions globally. Cell harvesting is the preferred method used in cancer cell-related studies including cancer cell databases (cancer cell lines), and other analyses and drug discovery in a microenvironment. The rising prevalence of such chronic diseases has led governments to provide R&D funding to research institutes and biotechnology companies to develop advanced therapeutics. Various 3D cell culture technologies have been developed by researchers and biotechnology companies such as Lonza Group and Thermo Fischer Scientific for research applications such as cancer drug discovery. The application of cell culture in cancer research is leading to more predictive models for research, drug discovery and regenerative medicine applications.

Platelet-rich plasma (PRP) therapy, a new biotechnology solution that has a heightened interest among researchers in tissue engineering and cell-based therapies, has various applications in the treatment of tissue healing in tendinopathy, osteoarthritis and muscle injury. It has been conventionally employed in orthopedics, maxillofacial surgery, periodontal therapy and sports medicines. PRP therapy can be used in the treatment of fat grafting, acne scars, and hair regrowth.

Major factors driving market growth include increasing healthcare costs and the high rate of adoption for modern medicines in emerging economies such as China and India. It has been estimated that India will witness a CAGR of REDACTED in the cell harvesting market during the forecast period. The active participation of foreign pharmaceutical companies has tapped the Indian healthcare sector with a series of partnerships and mergers and acquisitions, which in turn is positively impacting the growth of the market in this region. Consistent development and clinical trials for stem cell therapies, plus contribution from the government and private sectors through investments and cohesive reimbursement policies in the development of cancer biomarkers, is further fueling market growth. InSweden, a research team at Lund University has developed a device to collect fluid and harvest stem mesenchymal stem cells (MSCs). The device is developed with 3D-printed bio-inert plastics which, when used by doctors, can result in the safe extraction of fluids (medical waste) from the patients body. The liquid is then passed through a gauze filter for purifying thoroughly and MSCs are separated from the fluid by centrifugation and are grown in culture.

Follow this link:
Cell Harvesting Market 2018 Analysis Of Production, Future Demand, Sales And Consumption Research Report To 2023 - The Scarlet

Sophie (5) lit up a room and was a little inspiration – New Ross Standard

Sophie Walsh, who left this world on Tuesday (18th) aged five, was a ray of sunshine who brightened up the lives of everyone who was fortunate enough to meet her.

Sophie, like most children her age, was due to start school this week. After a long, courageous battle with cancer, she succumbed to the illness that afflicted her over three years at Crumlin Children's Hospital on Tuesday.

Born a perfectly healthy child on July 3, 2015, into a loving home, her parents Sandra and Thomas were overjoyed to bring her back to her freshly decorated room in Lacken Valley.

Sophie met all her milestones but just before her second birthday, Thomas and Sandra sensed there was something wrong.

'She was going off her food. We went to doctors, hospitals a couple of times, both in Waterford and Wexford. Then back to the GP and CareDoc. They were all putting it down as a viral thing that would run its course but nothing seemed to be getting any better,' Thomas said.

They brought Sophie to CareDoc one Sunday evening and a doctor noticed a lump which was examined at University Hospital Waterford and the next day Sophie, Thomas and Sandra left for Crumlin, the first of many visits.

'Our lives changed overnight,' Sandra said. 'Our consultant sat us down and laid out a treatment plan which was going to be up to two years. The doctors said it was going to be an intensive time.'

Sophie was diagnosed with neuroblastoma, a cancer of the central nervous system.

The prognosis was 50/50 as Sophie had an amplified version of the illness which made it harder to treat. Thankfully Sophie responded very well to treatment and after a few weeks her energy levels started improving.

'She was back to being normal, except without the hair. She completed ten rounds of chemotherapy and had a break over Christmas and had surgery for her tumour, from which she recovered well. She had her own stem cell transplant in March,' Thomas said.

Throughout, Sandra and Thomas were staying in the Ronald McDonald House near Crumlin on and off, their every waking moment by her side as Sophie recovered from the transplant and had 14 rounds of radiotherapy in St Luke's, being administered a general anaesthetic every day.

She recovered from her treatment and had five rounds, once a month of immune-therapy.

'She finished that in January 2019 and then she was finished. There was no evidence of disease.'

Throughout Sophie couldn't enjoy the social interactions other children take for granted.

'She couldn't have a normal childhood as she was susceptible to infections. She could have cousins and friends around (sometimes). When we could, we did. She was in isolation for 100 days after her bone marrow transplant. Sophie made loads of friends at Crumlin. There were families from throughout Ireland we met up there and became good friends with. She was in Tir na ng playschool (when she could). She was looking forward to starting school.'

Throughout the spring of 2019 Sophie was in great health. 'Everything was going good. She loved her dolls. She loved watching Youtube. Watching kids playing with toys. She loved to play. When she was feeling up to it she wanted to play and when she wasn't she watched TV.'

Recalling a really happy child, an old soul in a child's body, her parents said she was ahead of her years in terms of her conversations and speech. 'She was around adults a lot between nurses and doctors. She had a great imagination. She could pick up a book and even if she couldn't understand the words she'd make up a story from the pictures.'

Sandra said: 'She was very witty; very quick off the mark. She was stubborn as well. If she didn't want to do anything you couldn't change her mind; it was set and that was it.

'We often said she was an old person wrapped up in a small person's body.'

Sophie enjoyed a magical trip to Disneyland with her parents, revelling in meeting Mickey Mouse and all the Disney characters she had seen on TV.

'She loved it!' they said.

Having enjoyed great health all spring of last year, something showed up in a routine scan midway during the summer.

'It was very small and they couldn't be 100 per cent. We had to wait and see what happened. She did a biopsy in September which confirmed she had relapsed and, at that stage, we knew she would have a very poor prognosis of five or six per cent. But we didn't give up hope because she had such a good response the first time around so we thought she could do it again. She had a tough road.'

Due to the location of the cancer within the femur and her tender age, the bone broke the day after the biopsy.

Undeterred Sophie went around in her buggy to trick or treat that Hallowe'en, totally embracing the chance to get dressed up.

'She adapted so well to every challenge. She had a nice Christmas.'

Sophie continued getting treatments after Christmas. 'The treatment she was on wasn't working as well as they liked and there was more progression on it. They switched her onto a different treatment again in February. We were running out of options at this stage.'

Sophie's condition was being kept at bay with the chemotherapy. She still had a good quality of life, but less energy.

'We had been told that the chemo would only work for so long and the cancer can find ways around it and gets used to it. We were always hoping for a miracle and that something would come along.'

Sophie enjoyed a great fifth birthday with friends and family in the garden.

A few weeks later, Aoibhinn's Pink Tie charity staff arranged a princess party at the Horse & Hound for her.

'She had wanted to meet Elsa and Anna. She had her cousins and there was face painting. That was her last good day.'

That evening Sophie started complaining of pain and her leg became more and more swollen.

She was admitted to University Hospital Waterford the following week and a CT scan showed quick progression of the tumour.

Sophie was transferred to Crumlin to help her pain management.

She died on Tuesday, August 18.

'It happened so suddenly. She was tired from treatment. There was one of us with her at all times; we took it in turns.'

Both Thomas and Sandra, who have been out of work since the diagnosis to care for Sophie, said: 'Everything changed so quickly and with the diagnosis and the prognosis we didn't want to wait a second. We didn't want to be looking back in five or ten years time that we had missed out. We had three amazing years. It was just the three of us, especially during lockdown it was nice just to have that time, the three of us.'

They praised the nursing staff of the hospitals Sophie as cared in.

Thomas said: 'Throughout, the whole community were amazing; especially neighbours and local businesses. Even just in terms of support. She was treated like a mini celebrity in The Bakehouse and O'Briens. Everywhere she went on the town everybody knew her and was so good to her. She was a little character as well. Every day she'd say something that made you laugh. She wasn't always in good form but she could change so quick. She would never dwell on things and never left her illness define her; she just kinda got on with it and never talked about it.'

Some of the nurses attended Sophie's funeral, as did staff members from McDonald's in Waterford, a favourite destination for Sophie.

'The nurses left off balloons outside for her. They were so good to her. If she wanted a dance party they held a dance party, copying her moves. The Dunbrody ship was lit up gold for Sophie, ahead of cancer awareness month in September. She would have been starting school this week. We had picked a school and she was looking forward to starting big school.'

Sandra and Thomas left the house on Friday morning for their daughter's funeral.

'All of the neighbours were lined up on either side of the road. We had a garda escort down. Fr Tom Orr gave a lovely, personal eulogy. He was excellent to us and even called to Crumlin to see her. Members of the United Striders stood as guards of honour, as did Urban Gym and Tr na Ng staff.'

'You Are My Sunshine' rang out from the speakers at her funeral Mass, where not a dry eye could be found.

Sophie was laid to rest in St Stephen's Cemetery, not far from her home.

The family want to thank everyone involved in sharing their love of Sophie on Friday, from the guards of honour to their neighbours and the wider community.

Sandra and Thomas said the Ronald McDonald House and Aoibhinn's Pink Tie charities were tremendously supportive throughout the three years.

'When a diagnosis comes, it's rushed and people arrive at John's Ward [in Crumlin] with just the clothes on their back. Even to have a toothpaste and brush.'

They recall in hushed tones, five years of happy memories with Sophie. 'Just being so happy; a family - the three of us. She could just light up a room; she had a presence about her. She would make anybody laugh and left a lasting impression on people who were just drawn to her. She could come out with anything. She told it as it was.'

They spoke of a child who inspired them to have a positive outlook on life and cherish each day as it comes, no matter what.

'For a five-year-old she was so happy go lucky. She inspired us. One day in the hospital she was colouring for the nurses and started colouring squiggles. I said why aren't you doing it properly and she said "life is too boring to just stay between the lines". There is a lot you can learn from a five-year-old, about outlook on life and how to deal with adversity. If Sophie spiked a temperature it means a few days in hospital and there was never any complaining.'

Sophie is dearly missed by Thomas and Sandra, her grandfathers Pat and Billy, aunts, uncles, cousins, extended family and friends.

New Ross Standard

Follow this link:
Sophie (5) lit up a room and was a little inspiration - New Ross Standard

Rare group of HIV patients don’t need drugs to suppress virus due to way it integrates in their DNA – Brinkwire

A woman diagnosed with HIV almost 30 years ago may have been cured of the virus without taking drugs or having a bone marrow transplant.

Scientists have studied Loreen Willenberg for decades, with the 66-year-old insisting she has never taken medication to keep the virus at bay. Doctors say her body fights the infection naturally.

But now academics claim she can be added to the list of cured HIV patients, next to theBerlin patient Timothy Ray Brown and the London patientAdam Castillejo.

Both Mr Brown, 54, and Mr Castillejo, 40, had cancer and were given a bone marrow transplant from adonor with HIV-resistant genes to wipe out their disease and the AIDS-causing virus in one fell swoop.

Ms Willenberg who was diagnosed in 1992 and is considered an elite controller because she possesses the rare ability to suppress the virus by itself never had the risky treatment.

Researchers at the Ragon Institute of MGH, MIT and Harvard found no traces of HIV in the Californian woman through standard tests.

Advanced technology that analysed 1.5billion of Ms Willenbergs blood cells found tiny quantities of the virus, meaning she isnt HIV-free. But the doctors revealed her immune system had rendered the leftover traces incapable of reproducing.

Dr Sharon Lewin, director of The Peter Doherty Institute for Infection and Immunity in Australia, told the New York Times: She could be added to the list of what I think is a cure, through a very different path.

Another 63 patients not on anti-retroviral drugs were also found to have traces of HIV that were unable to reproduce.

The team, whose work was published in the journal Nature, say the findings provide evidence that these people have achieved a functional cure.

Elite controllers are only believed to account for 0.5 per cent of the 37million people living with HIV across the world.

Researchers found that, because of where these patients have the virus encoded in their DNA, the pathogen is unable to make copies of itself. Thiskeeps the virus below detectable levels, which makes it untransmissible.

Once a person contracts HIV, the virus sets about attacking and destroying immune cells that normally protect the body from infection.

In the last decade, doctors have gained a much improved understanding of how to control HIV. The rate of deaths from the disease has plummeted since the peak of the AIDS epidemic in the early 1980s.

It is treatable and doctors recommend taking a combination or cocktail of drugs known as antiretroviral therapy, or ART.

Within six months of taking the medication once a day, a persons viral load will be virtually undetectable, but the body wont be completely rid of it.

This is because the virus hides in the body by integrating its genetic material into DNA and forming whats known as a latent reservoir.

But ART which can cause nausea, diarrhoea, headaches and fatigue isnt able to destroy these reservoirs but if an HIV patient ceases taking the cocktail, the virus can start making copies of itself again.

Elite controllers have latent reservoirs, but they dont need to take drugs to stop the virus from spreading throughout the body.

They naturally maintain what other people need ART to do, co-author Dr Mathias Lichterfeld, an infectious disease physician at Ragon, told HealthDay.

For the study, the team looked at blood samples from 64 elite controllers and 41 HIV patients taking ART.

Results showed that, in elite controllers, HIV genetic material was found in so-called gene deserts of the DNA. These are where there is little gene activity so the virus is unable to make copies of itself and instead remain in a blocked and locked state.

Lead author Dr Xu Yu, an associate professor of medicine at Harvard Medical School, said: This positioning of viral genomes in elite controllers is highly atypical.

In the vast majority of people living with HIV-1, HIV is located in the active human genes where viruses can be readily produced.

Dr Yu calls this a functional cure, which occurs when a virus is still in the body but can be controlled without medication.

The researchers believe this is because, in the early days of infection, the immune systems of elite controllers killed the virus after it integrated into DNA regions with a great deal of gene activity.

The team says the findings could lead to a cure, either by creating drugs that replicate the phenomenon of elite controllers or that eliminate HIV thats integrated in parts of the DNA that have substantial gene activity.

Elite controllers carry a mutation of CCR5, which prevents it from expressing, which essentially blocks the gene altogether. Experts say the genetic quirk has descended from northern Europeans.

The study comes after a Brazilian man in his mid-30s with HIV went into long-term remission after treatment with drugs and vitamin B3.

Doctors last month revealed the case of the Sao Paolo patient, who is understood to be the first HIV patient in the world to go into remission following pharmaceutical treatment.

And scientists last year revealed that a third HIV-positive patient in Germany may be free of the virus after undergoing the risky bone-marrow transplant.

But neither the Sao Paolo patient orthe Dsseldorf patient had been free of the virus for long enough to be considered cured.

For example, cancer patients have to be in remission for five years before they are labelled as cured.

Unfortunately, the Berlin and London patients cases do not change the reality much for the millions of people living with HIV.

The treatment is unlikely to have potential on a wider scale because both Mr Castillejo and Mr Ray Brown were given stem cells to treat cancer, not HIV.

Stem cell and bone marrow transplants are life-threatening operations with huge risks. Dangers lie in the patient suffering a fatal reaction if substitute immune cells dont take.

Mr Ray Brown, who is from Seattle but was treated in Germany, has been HIV-free for 12 years without medication.

But Mr Castillejo, whose mental health had spiralled drastically over the years and even led him to consider ending his life, was only treated in 2016.

See the rest here:
Rare group of HIV patients don't need drugs to suppress virus due to way it integrates in their DNA - Brinkwire

Hematopoietic Stem Cell Transplantation (HSCT) Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2022 -…

The global Hematopoietic Stem Cell Transplantation (HSCT) market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Hematopoietic Stem Cell Transplantation (HSCT) market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Hematopoietic Stem Cell Transplantation (HSCT) market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Hematopoietic Stem Cell Transplantation (HSCT) market. The Hematopoietic Stem Cell Transplantation (HSCT) market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2773144&source=atm

segment by Type, the product can be split into Allogeneic Autologous Market segment by Application, split into Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2773144&source=atm

The Hematopoietic Stem Cell Transplantation (HSCT) market research covers an exhaustive analysis of the following data:

The Hematopoietic Stem Cell Transplantation (HSCT) market research addresses critical questions, such as

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2773144&licType=S&source=atm

The global Hematopoietic Stem Cell Transplantation (HSCT) market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

More here:
Hematopoietic Stem Cell Transplantation (HSCT) Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2022 -...

Global Cell Proliferation Kit Market Insights And Extensive Research (2020-2025) : Biological Industries, Thermo Fisher – The Daily Chronicle

Eon Market Research Publish New Market Report On- Cell Proliferation Kit Market 2020 Global Analysis, Size, Share, Trends and Growth, Forecast 2025

The Cell Proliferation Kit Market Report also provides extensive research on the Top key players in this market and detailed insights into theircompetitiveness. Key business strategies such as acquisitions and acquisitions, alliances, collaborations, and contracts adopted by Top keyplayers are also recognized and analyzed in the report. For each Industry, the report recognizes competitors, product types, applications andspecifications, prices, Trends, and gross margins. The study analyzes the market in terms of revenue across all the major markets.

Market Summary :

Different Top key players such as Biological Industries, Thermo Fisher Scientific, Sigma-Aldrich (Merck), BD Biosciences, GE, PerkinElmer, Millipoore (Merck), Bio-Rad, Biotium And More have been profiled to get better insights into the businesses. It offersdetailed elaboration on different Leading level industries which are functioning in global regions. Additionally, it gives detailedelaboration on different government rules, policies, and plans to understand the overall scope of the Cell Proliferation Kit Market. In the global Cell Proliferation Kit Market, various important aspects such as regional market insights, region-wise trends, country-level analysis,competitive landscape, company market share analysis, and key company profiles are covered. The latest Cell Proliferation Kit Market report fine-tunes thescope of typical characteristics with which vendors are reviewed. For reviewing the global Cell Proliferation Kit Market, the report uses varioustechniques such as surveys, interviews, and structured discussions with participants, end-users, and market leaders.

For Better Understanding Go With This Free Sample Report Enabled With Respective Tables and Figures( Get Instant 10% Discount ):https://www.eonmarketresearch.com/sample/68568

Cell Proliferation Kit Market regional analysis covers the following regions North America, Europe, Asia-Pacific, South America, Middle East & Africa.

Product Segment Analysis of the Global Cell Proliferation Kit Market are:

Colorimetric Detection Method Fluorescent Detection Method Other

Applications of the Global Cell Proliferation Kit Market are:

Clinical Industrial and Applied Science Stem Cell Research

Buy This Premium Report: https://www.eonmarketresearch.com/buy/68568

Research Objectives Of Cell Proliferation Kit Market:

* This report provides pin-point analysis for changing competitive dynamics

* It provides a forward-looking perspective on different factors driving or restraining the market growth

* It provides a six-year forecast assessed on the basis of how the market is predicted to grow

* It helps in understanding the key product segments and their future

* It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

* It helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments

Any Questions? Feel Free To Enquire Here. We will Put You On The Right Path: https://www.eonmarketresearch.com/enquiry/68568

Points To Buy This Market Report Covers:

* It will guide you in considering different perspectives on the market with the assistance of Porters five powers examination.

* Distinguish the new advancements, mark

* A valuation that each of these regions accounts for in the industry

Buyers who are searching for top-line data regarding Cell Proliferation Kit market can get benefit from this report as its an essential resource which covers market size data, textual and graphical analysis of market growth trends and other economic information. In the resulting part, the report describes industry sales channels, distributors, traders, dealers, appendix and data sources.

[ *** If You Have Any Special Requirements, Please Let Us Know And We Will Offer You The Report As You Want. *** ]

About Us:

Eon Market Research (EMR) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Eon Market Research offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Get in Touch with Us :

Eon Market Research

Phone: +1 703 879 7090

Email: [emailprotected]

More here:
Global Cell Proliferation Kit Market Insights And Extensive Research (2020-2025) : Biological Industries, Thermo Fisher - The Daily Chronicle

Foetal cells are used to make the Oxford coronavirus vaccine. But they came from a foetus in 1973 – ABC News

Religious leaders have raised ethical doubts over one of Australia's primary coronavirus vaccine hopes because scientists have used foetal cells in its development.

Developers at Oxford University and pharmaceutical firm AstraZeneca are using cell lines from an electively aborted foetus in the vaccine candidate, with Anglican, Catholic and Greek Orthodox leaders questioning the practice.

But using foetal cells in vaccine development isn't new and the Catholic Church has previously expressed qualified support for the use of vaccines derived from these cells under certain circumstances.

We spoke to Bill Lott, a virologist at QUT's Institute of Health and biomedical innovation, to understand the role of foetal cells in vaccine development.

The foetal cells used in vaccine development are derived from a small number of foetuses which were legally terminated decades ago.

The Oxford vaccine uses HEK (human embryonic kidney) 293 cell lines, obtained from a female foetus in the Netherlands in 1973.

"We're using tissues that were from foetuses that were aborted 40, 50, 60 years ago," Dr Lott said.

"It doesn't require newly aborted foetuses."

While living human cells can only divide around 50 times, those foetal cells have been genetically modified so they can divide an infinite number of times.

"That's why we can use the cells that we harvested [decades ago] today," Dr Lott said.

"They're not the actual original cells, they've been immortalised and then propagated over the decades."

This means we'll never need to replace specimens used in development.

"Just by analogy, buying ivory is illegal [because] if you create a market for ivory, then it creates the demand to kill more elephants," Dr Lott said.

"In this case, that's not happening because these foetuses were aborted 60 years ago, 50 years ago, and using these immortalised tissues now is not going to create a need to go and get new ones."

In fact, scientists would prefer to keep using HEK 293 cell lines because they have been repeatedly tried and tested in a laboratory setting and found to be safe.

"When you're making a vaccine you require safety testing," Dr Lott said.

"If we went back and used a different cell type, you're throwing an unknown into the consideration.

"So that will severely slow down your ability to make these things.

"Using HEK 293, we've used it for decades and we know that it's safe."

This week, Australia's Deputy Chief Medical Officer Nick Coatsworth pointed out the use of foetal cells had been a "reality" in past vaccine development.

"The reality for vaccines is that they need cell cultures in order for us to grow them," he said.

"The human cell is a really important part of their development.

"There are strong ethical regulations surrounding the use of any type of human cell, particularly foetal human cells.

"This is a very professional, highly powered research unit at Oxford University.

"I think we can have every faith that the way they have manufactured the vaccine has been against the highest of ethical standards internationally."

Breaking down the latest news and research to understand how the world is living through an epidemic, this is the ABC's Coronacast podcast.

So, how do foetal cells help with vaccine development? Dr Lott explained they operate like a "vaccine factory".

First, scientists need to develop the vaccine candidate and then combine it with an adenovirus vector.

An adenovirus is a particular type of common virus that causes illnesses like bronchitis, pneumonia and a sore throat.

For instance, when you get a cold, you may be infected with an adenovirus, a coronavirus or a rhinovirus.

A vector is an organism that spreads infection by moving pathogens from one host to another.

So an adenovirus vector? "That's an adenovirus that has been sort of emptied out and then you put a different kind of genome in there to make protein," Dr Lott said.

The next step is to put the vaccine/adenovirus vector combination into a big vat of foetal cells.

"The viral vector infects these HEK 293 cells really, really efficiently," Dr Lott said.

"One reason why you use the HEK 293 is because you get essentially 100 per cent infection with the adenoviral vector.

"And what it does is it turns the HEK 293 cells into a vaccine factory."

What do we mean by "vaccine factory"? Dr Lott explains foetal cells begin producing "tons and tons of that modified adenovirus" which they then "spit out into the liquid bit of the cells" called the cell culture media.

"[The foetal cells] start cranking out this massive amount of modified adenovirus, and then you purify those things away from the cell tissue," he said.

"You pull the [cell] media off, and it's just going to be full of the vaccine and essentially no tissue.

"And that's what your vaccine is."

The foetal cells will operate as this "vaccine factory" regardless of whether the vaccine is effective or not so the next step generally involves animal and then human trials of varying scale.

Inherent in the whole process is stripping away the conditioned cell media, where the foetal cells are contained.

The head of the World Health Organization has warned we may never get a silver bullet for COVID-19. What could that future look like in Australia?

That means a successful vaccine developed using foetal cells will have no remnants of those cells in the final product.

"You purify the vaccine away from the cells that they were grown in, and then you destroy all the cells," Dr Lott said.

"So then you're going to take that liquid and you'll purify it some more, but there are not going to be any [foetal] cells in there.

"There's nothing left when it becomes the vaccine that gets delivered."

Foetal tissue has been used with innovative effect in various strands of medical research.

The difference is some of those processes require fresh foetal cells not the "immortalised" cells vaccine developers can use.

"The vaccine work is pretty straightforward," Dr Lott said.

"But cancer research, the research into the mechanisms of various things cystic fibrosis, haemophilia, rheumatoid arthritis that all required fresh foetal tissue."

Scientists studying Zika virus used foetal cells to discover that the virus crossed the placental membrane and caused brain damage in unborn foetuses.

"[That research] brought out a whole raft of therapies and protections for unborn foetuses [and] "saved a lot of lives, including [the lives of] unborn foetuses," Dr Lott said.

Foetal cell lines have been used in the development of various vaccines, including for chicken pox, Ebola, polio, rubella, shingles, Hepatitis A, and rabies.

Foetal tissue has also facilitated breakthroughs in the treatment of various medical issues including cystic fibrosis, haemophilia, IVF, Parkinson's and Alzheimer's diseases, AIDS, and spinal cord injuries.

Scientists have many different methodologies for developing vaccines and there are a variety of reasons why foetal cells aren't always used.

Billions are being poured into the race to find a coronavirus vaccine, with the winner owning a powerful political tool. During the last pandemic an Australian company got there first.

"Some of them don't use it because of ethical issues," Dr Lott said.

"Some of them don't use it because they're not using an adenovirus [vector], so they don't really need the HEK 293.

"And there are other [development] strategies.

"There's an mRNA strategy that's very popular.

"So some of them don't require it."

The development of a coronavirus vaccine was time critical because of the virus' devastating public health and economic impacts, Dr Lott said.

Therefore, it was important for scientists to diversify their methodologies in order to develop a vaccine as quickly as possible.

Both stem cells and foetal cells are critical to innovations in medical research but what's the difference between the two?

Dr Lott explains stem cells are basically the earliest iteration of a foetal cell before the cell differentiates itself into, for example, a hair cell, liver cell, eye cell or skin cells.

"A stem cell is simply a cell that can turn into a different cell types," Dr Lott said.

"That first embryonic stem cell can eventually turn into any kind of cell in your body.

"So you've got embryonic stem cells, and then you've got adult stem cells, and in between are the foetal stem cells [which] are partially differentiated.

"So foetal cells contain not only stem cells some of the foetal cells have already differentiated into their final cell type."

In 2005 and again in 2017, the Catholic Church expressed qualified support for the use of foetal-cell-derived vaccines but only if there was no available alternative.

A 2005 "moral reflection" issued by Pope Benedict XVI specifically addressed the issue.

"As regards the diseases against which there are no alternative vaccines which are available and ethically acceptable, it is right to abstain from using these vaccines if it can be done without causing children, and indirectly the population as a whole, to undergo significant risks to their health," the Pope wrote.

"However, if the latter are exposed to considerable dangers to their health, vaccines with moral problems pertaining to them may also be used on a temporary basis.

"We find a proportional reason, in order to accept the use of these vaccines in the presence of the danger of favouring the spread of the pathological agent."

In 2017, the life ethics arm of the Catholic Church issued a statement that: Catholic parents could vaccinate their children with a "clear conscience" that "the use of such vaccines does not signify some sort of cooperation in voluntary abortion".

Earlier this year and in the context of the coronavirus vaccine race, John Di Camillo, an ethicist with the National Catholic Bioethics Center, confirmed: "One is allowed to make use of [vaccine derived from foetal tissue] where there's a serious threat to the health or life of the individual, or of the greater population.

"This does not amount to a strictobligationto use it, but it certainly can be a legitimate choice in conscience if theres that serious reason, and there's no other reasonable alternative."

Follow this link:
Foetal cells are used to make the Oxford coronavirus vaccine. But they came from a foetus in 1973 - ABC News